Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib With or Without Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT04034927Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Dec 2019; status: active, not recruiting.
02
Drugs
tremelimumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04034927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034927.